Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTARES PHARMA, INC.

(ATRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ANTARES PHARMA, INC. : Regulation FD Disclosure (form 8-K)

08/18/2021 | 10:45am EDT

Item 7.01 Regulation FD Disclosure.

A copy of the Antares Pharma, Inc. (the "Company") updated investor presentation slides that the Company intends to use effective immediately is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.


The information disclosed under this Item 7.01, including Exhibit 99.1 hereto,
is being furnished and shall not be deemed "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by
reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended, except as expressly set forth in such
filing.
Item 9.01  Financial Statements and Exhibits.
(d) Exhibits.
   Exhibit
     No.            Description

99.1                  Antares Pharma, Inc.     Invest    or Presentation    ,     August     2021
104                 Cover Page Interactive Data File (embedded within the Inline XBRL document)


--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ANTARES PHARMA, INC.
05:06aANTARES PHARMA : Enters into exclusive license agreement with lipocine for tlando in u.s.
AQ
05:06aLIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO
AQ
10/18LIPOCINE : Signs Deal with Antares Pharma for Commercialization of Tlando in the US; Share..
MT
10/18ANTARES PHARMA : Strikes Exclusive License Agreement For Oral Testosterone Replacement The..
MT
10/18ANTARES PHARMA : ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH LIPOCINE FOR TLANDO® IN U.S ..
PU
10/18ANTARES PHARMA, INC. : Other Events (form 8-K)
AQ
10/18ANTARES PHARMA : Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S.
GL
09/30ANTARES PHARMA : Starts Phase 1 Study of ATRS-1902 Drug for Acute Adrenal Insufficiency Tr..
MT
09/30ANTARES PHARMA : Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
AQ
09/30Antares Pharma, Inc. Initiates Phase I Study for ATRS-1902 for Adrenal Crisis Rescue
CI
More news
Analyst Recommendations on ANTARES PHARMA, INC.
More recommendations